For example, a p110δ-selective inhibitor idelalisib was recently approved to treat several types of blood malignancies including chronic lymphocytic leukemia, relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma44–46. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.